EP2023906A2 - Compositions à libération retardée de formes à libération prolongée de venlafaxine - Google Patents

Compositions à libération retardée de formes à libération prolongée de venlafaxine

Info

Publication number
EP2023906A2
EP2023906A2 EP07761266A EP07761266A EP2023906A2 EP 2023906 A2 EP2023906 A2 EP 2023906A2 EP 07761266 A EP07761266 A EP 07761266A EP 07761266 A EP07761266 A EP 07761266A EP 2023906 A2 EP2023906 A2 EP 2023906A2
Authority
EP
European Patent Office
Prior art keywords
venlafaxine
controlled release
release
active pharmaceutical
delayed controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07761266A
Other languages
German (de)
English (en)
Inventor
Krishna Vishnupad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurosci Inc
Original Assignee
Neurosci Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosci Inc filed Critical Neurosci Inc
Publication of EP2023906A2 publication Critical patent/EP2023906A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to delayed controlled release compositions for oral administration of at least one form of venlafaxine, to processes for their preparation and to their medical use.
  • the delayed modified release composition relates to a delayed controlled release composition of at least one form of venlafaxine.
  • a delayed controlled release regimen for pharmaceuticals are desirably maintained within their therapeutic window so that by which an acceptable therapeutic concentration of drug at the site(s) of action is attained after a selected period of ingestion advantageous to the active pharmaceutical and is then maintained constant for the duration of the treatment.
  • therapeutic "steady-state" plasma concentrations of a drug can be achieved promptly and maintained by the multiple administrations of conventional oral dosage forms.
  • patient compliance is one of the greatest limitations. These limitations have led to the need to consider presenting therapeutically active pharmaceuticals in extended-release or delayed extended release preparations.
  • oral ingestion is the traditionally preferred route of drug administration, providing a convenient method of effectively achieving both local and systemic
  • Extended-release (ER) delivery systems should provide a uniform concentration/amount of the drug at the absorption site and thus, after absorption, allow maintenance of plasma concentrations within a therapeutic range over an extended period of time, which can minimize side effects and also reduces the frequency of administration. It is desirable that ER dosage forms release drug slowly, so that plasma concentrations are maintained at a therapeutic level for a prolonged period of time. As a result, ER products provide numerous benefits compared with immediate-release compositions, including greater effectiveness in the treatment of chronic conditions, reduced side effects, greater convenience, and higher levels of patient compliance due to a simplified dosing schedule. However, it is desirable in some pharmaceuticals to combine an extended release delivery system with a delay in an initial release
  • Controlled-release formulations have been described in the prior art and many methods have been used to provide controlled-release pharmaceutical dosage forms in order to maintain therapeutic serum levels of medicaments and to minimize the effects of missed doses of drugs caused by a lack of patient compliance.
  • Anti-depressants and psychotropic drugs are excellent candidates for controlled-release formulations as discontinuation of these drugs, most often as a result of a lack of patient compliance due to a complicated or multiple daily dosing schedule, can often result in the lack of efficacy in these medication and problems with severe discontinuation symptoms.
  • Venlafaxine which is chemically designated as (R/S)-l-[2-(dimethylamino)-l-
  • (4methoxyphenyl)ethyl]cyclohexanol or ( ⁇ H-f ⁇ [ ⁇ -(dimethylamino)methyl]p- methoxybenzyl]cyclohexanol is a bicyclic compound with antidepressant properties affecting neurotransmitters within the brain.
  • These neurotransmitters can for example be serotonin, dopamine, and norepinephrine.
  • Neurotransmitters are manufactured and released by nerve cells. The neurotransmitters migrate to neighboring nerve cells and cause the cells to become more or less active. It is believed that an imbalance in these neurotransmitters is the cause of depression and also may play a role in anxiety. Venlafaxine is believed to work by inhibiting the release or affecting the action of these neurotransmitters.
  • Venlafaxine is chemically unrelated to other antidepressants, but is sometimes categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI). At low dosages, venlafaxine blocks serotonin reuptake, similarly to a selective serotonin reuptake inhibitor (SSRI). At medium dosages, venlafaxine blocks the reuptake of norepinephrine as well as serotonin. At high dosages, venlafaxine blocks the reuptake of norepinephrine, serotonin and is also a weak blocker of the reuptake of dopamine. Unfortunately, current formulations of venlafaxine do not allow higher doses associated with this dual mechanism of action.
  • SNRI serotonin-norepinephrine reuptake inhibitor
  • SSRI selective serotonin reuptake inhibitor
  • venlafaxine blocks the reuptake of norepinephrine as well as seroton
  • Venlafaxine is well absorbed after oral administration and its metabolism has been well documented. Following absorption, venlafaxine undergoes extensive pre-systemic metabolism in the liver, primarily to 0-desmethyIvenIafaxine (ODV), but also to N-desmethylvenlafaxine (NDV), N,O-didesmethylvenlafaxine (DDV), and N.N.O-tridesmethyivenlafaxine (TDV).
  • ODV 0-desmethyIvenIafaxine
  • NDV N-desmethylvenlafaxine
  • DDV N,O-didesmethylvenlafaxine
  • TDV N.N.O-tridesmethyivenlafaxine
  • venlafaxine Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor active metabolites (27%). Renal elimination of venlafaxine and its metabolites is the primary route of excretion.
  • the metabolic pathway of venlafaxine can be summarized as follows: Venlafaxine's elimination half-life of about 4 hours is short, and its active metabolite has a half- life of about 8 hours. This results in venlafaxine needing to be administered twice daily and a lack of patient compliance in keeping to this daily dosing schedule has the potential to produce discontinuation problems. Unfortunately, sudden discontinuation of venlafaxine can result in
  • venlafaxine be formulated in a delayed controlled-release oral formulation.
  • Venlafaxine as its hydrochloride salt, is available as a second-generation extended- release tablet and is marketed under the brand name Effexor® XR for once daily use. Such a formulation has eliminated the discontinuation problems seen with instant release Effexor®, the first-generation immediate-release form of venlafaxine, which is usually administered twice daily. Extended-release formulations of venlafaxine have been described in the prior art. U.S. Pat. Nos.
  • 6,274,171, 6,403,120, and 6,419,958, for example, disclose formulations comprising a therapeutically effective amount of venlafaxine hydrochloride in film-coated spheroids.
  • the spheroids comprise a core having venlafaxine hydrochloride, microcrystalline cellulose, and optionally hydroxypropylmethylcellulose.
  • the cores are coated with a mixture of ethylcellulose and hydroxypropylmethylcellulose and subsequently packaged into hard gelatin capsules.
  • a compressed core comprising a burst controlling agent as well as a disintegrant characterizes the formulation.
  • the core is coated with a relatively rigid water insoluble, hydrophobic polymer, in which particles of water insoluble but hydrophilic material are embedded. These particles form channels upon contact with aqueous medium, which imbibe liquid and cause the burst-controlling agent to burst the coating thereby enabling the delayed-burst release of the venlafaxine.
  • the '044 patent apparently also teaches that the formulation provides for a 30% higher bioavailability of the venlafaxine in fasting volunteers when compared to extended-release formulations of venlafaxine presently available on the market.
  • the present disclosure relates to a modified delayed sustained release formulation of at least one pharmaceutical acceptable form of venlafaxine.
  • the modified delayed release composition of venlafaxine is provided by a blend of polymers in a core formulation.
  • This core formulation having extended release polymers is coated with a non- permeable polymer blend comprising a water in-soluble polymer and an enteric coating polymer that does not disintegrate substantially in either acid or base mediums for up to about 4 hours.
  • the sustained release core tablet is made up of an active
  • venlafaxine hydrochloride an extended release polymer such as ethyl cellulose, hydroxyl methyl cellulose, mixtures thereof or the like, which retard the release of the active pharmaceutical once the non-permeable polymeric delayed release coating according to the disclosure has disintegrated.
  • extended release polymers can be used alone or in combination with at least one other polymer.
  • the core formulation containing these extended release polymers can be used with other therapeutic agents or combinations of therapeutic agents other than venlafaxine.
  • the delayed release coating according to the disclosure is provided by a innovative
  • the polymeric coating blend according to the disclosure is substantially non-permeable to either acid or alkaline conditions for at least up to about 4 hours. Approximately 4 hours after ingestion the non- permeable coating disintegrates and the sustained released core releases the active pharmaceutical in a controlled extended manner. According to the disclosure this delayed sustained release formulation prevents nausea and emesis by not releasing any substantial amount of drug into the stomach thereby preventing nausea and emesis associated with current formulations.
  • the non-permeable coating membrane is made of a water in-soluble polymer such as but not limited to ethyl cellulose, cellulose acetate, methacrylates, mixtures thereof or the like.
  • the enteric coating polymers include but are not limited to cellulose acetate phalate, hydroxypropyl methyl cellulose phalate, methacrylic acid phalate, mixtures thereof or the like. It is contemplated within the disclosure that other water in-soluble polymers known in the art may be used alone or in mixtures thereof.
  • the non-permeable coating formulation according to the disclosure is about 45% by weight ethyl cellulose, 55% by weight enteric coating and a plasticizer.
  • the coating formulation according to the invention is a blend of about 48% of ethyl cellulose and cellulose acetate, enteric coating of about 52% and a plasticizer.
  • the coating formulation according to the invention is a blend of about 46% of ethyl cellulose and cellulose acetate, enteric coating of about 54% and a plasticizer.
  • an object of the innovative formulation is that the extended release manner of the active pharmaceutical is substantially provided by the extended release polymers within the core formulation.
  • an object of the innovative formulation is that the core formulation is coated with a polymer blend forming a non-permeable coating according to the disclosure that is stable in both acid and alkaline environments for up to about 4 hours.
  • the combination of the non-permeable coating with the extended release core formulation allows peak plasma levels of the active pharmaceutical up to about 8-12 hours after ingestion and prevents substantial release of the active pharmaceutical within the stomach.
  • an object of the innovative formulation is that the extended
  • a core that further comprises at least one filler selected from the group consisting of lactose monohydrate, anhydrous lactose, mannitol, sorbitol, microcrystalline cellulose, dibasic calcium, calcium sulfate and mixtures thereof.
  • the at least one filler comprises up to about 85% by weight of the core dry weight
  • the filler is lactose monohydrate, and comprises by weight about 5- 35% by weight of the core dry weight.
  • an object of the innovative formulation is that the extended release manner of the active pharmaceutical is provided within a compressed core that further comprises at least one pharmaceutically acceptable lubricant selected from the group consisting of magnesium stearate, talc, stearic acid, sodium stearyl fumarate, calcium stearate, vegetable oil, silica gel, colloidal silicon dioxide, and mixtures thereof.
  • the at least one lubricant comprises from about 0.02 to about 10%, preferably from about 0.5 to about 5%, more preferably from about 0.5 to about 2% by weight of the core dry weight.
  • the lubricant in one illustrative embodiment is magnesium stearate and comprises about 0.75% of the core dry weight.
  • the compressed core tablet formulation allows for higher doses of the active pharmaceutical and in the case of venlafaxine allows up to about 300mg within a single tablet. It is yet a further object of the invention that a tablet containing higher dose of venlafaxine enables greater patient compliance and greater efficacy as it is thought that the dual mechanism of action is only present within higher dosage forms.
  • an object of the innovative formulation is that the active pharmaceutical is a pharmaceutically acceptable salt of venlafaxine selected from the group consisting of venlafaxine hydrochloride, venlafaxine besylate, venlafaxine maleate, and venlafaxine fiimarate.
  • an object of the innovative formulation is that the extended release manner of the active pharmaceutical is provided within a core having an extended release polymer that further comprises at least one pharmaceutically acceptable binder selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, polyethylene oxide, polyvinylpyrrolidone, copovidone, carbomers, carragheen, polyvinylalcohol and mixtures thereof.
  • the at least one binding agent comprises by weight from about 10 to about 80%, preferably from about 10 to about 40% by weight of the core dry weight.
  • the at least one binding agent in one illustrative embodiment comprises a mixture of at least two binding agents, most preferably hydroxypropylmethylcellulose (13%) and polyvinylpyrrolidone
  • the binding agent is copovidone.
  • the active agent is double granulated with a first granulation with a binding agent such as Povidone K-30 and then a further granulation with a binding agent such as Surelease® Clear e-7-19040 (Colorcon, West Point, PA).
  • a binding agent such as Povidone K-30
  • a binding agent such as Surelease® Clear e-7-19040 (Colorcon, West Point, PA).
  • the double granulation improves compressibility and minimizes hygroscopicity.
  • an object of the innovative formulation is that the extended release manner of the active pharmaceutical is provided within a core coated by a non-permeable membrane coating that is made of a water insoluble polymers such as but not limited to ethyl cellulose, cellulose acetate, methacrylates or the like.
  • the enteric coating polymers include but are not limited to cellulose acetate phalate, hydroxypropyl methyl cellulose phalate, methacrylic acid phalate, mixtures thereof or the like.
  • the non-permeable membrane according to the disclosure has at least one plasticizer that is selected from the group consisting of citrate esters, dibutyl sebacate, dibutyl pthalate, triacetin, castor oil, polyalkyleneglycol, fatty acids, and
  • the at least one plasticizer is stearic acid and comprises by weight from about 10 to about 15% of the coating weight.
  • an object of the innovative formulation is that the extended release manner of the active pharmaceutical is provided so that the T max of the composition of the disclosure compared to the reference product for venlafaxine is delayed by about 4 hours when the composition is administered under fed or fasting conditions.
  • an object of the innovative formulation is that the extended release manner of the active pharmaceutical is provided so that the absorption delayed controlled release pharmaceutical composition for oral administration according to the disclosure is suitable for once daily dosing comprises: a) a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, and pharmaceutically acceptable excipient; at least one extended release polymer and b) a non permeable coating substantially surrounding said core, said non-permeable coating comprising a water-insoluble water-permeable film-forming polymer and an enteric coating polymer that is non-permeable to either acid of alkaline conditions for at least up to 4 hours said non-permeable coating further comprising a plasticizer, wherein said non-permeable composition provides delayed controlled release of said at least one form of venlafaxine
  • a further object of the innovative formulation is that the extended release manner of the active pharmaceutical is provided so that the absorption delayed controlled release pharmaceutical composition for oral administration according to the disclosure is dose proportional for 150mg, 225mg, 300mg and 450mg doses.
  • Fig. 1 is a graphic depiction of cumulative dissolution profile comparison of venlafaxine
  • Fig. 2 is a graphic depiction of cumulative dissolution profile comparison of venlafaxine HCI 150, tablets according to the invention with the referenced brand product.
  • Compressibility within drug manufacturing is a problem, which not only affects the processing characteristics and machinability of a drug blend but also affects the final compressed tablet form.
  • a drug such as venlafaxine, which is poorly compressible and hygroscopic, is manufactured special precautions have to be taken to compress such drugs such as maintaining the relative humidity value below about 50% RH during manufacturing and packaging.
  • venlafaxine with a suitable binder.
  • venlafaxine is pre-granulated with a binder using either a dry or wet process and it is only mixed with the rate controlling polymers.
  • the polymers may or may not be wetted and remain in dry state, their performance is maximized and hence they can be employed in lower quantities and yet obtain desired dissolution profiles.
  • it has been surprisingly
  • a multi step granulation of an active ingredient such as venlafaxine improves compressibility and minimizes hygroscopicity.
  • venalafaxine is granulated with a binder such as povidone k-30 and then further granulated with an aqueous ethylcellulose dispersion such as Surelease®, clear E-7- 19040 (Colorcon, West Point, PA).
  • a binder such as povidone k-30
  • an aqueous ethylcellulose dispersion such as Surelease®, clear E-7- 19040 (Colorcon, West Point, PA).
  • Surelease® clear E-7- 19040
  • Tablets formulated according to the invention have been found to have a tablet weight reduction and size of at least 20% over marketed formulation allowing for tablets formulations having higher dosage strength. This is an important advantage in improving patient compliance. Moreover due to the reduced weight it is also possible to make dose weight proportionate tablets for the varying strengths of venlafaxine tablets. Those skilled in the art in commercial pharmaceutical production will appreciate the advantages obtained by having dose weight proportionate formulations since such formulations dramatically reduce the operation costs and labor involved in manufacturing separate dose dependent blends.
  • compositions of the present invention comprising venlafaxine granules essentially bound with about 0.1% to about 10% binder, preferably about 0.2% to about 5% binder and most preferably about 0.25% to about 4.5% binder and dispersed in a rate-controlling matrix of hydrophilic polymers are explained hereunder in greater detail with respect to individual components and their working ranges.
  • the various pharmaceutically acceptable salts of venlafaxine may be used, in one illustrative embodiment the preferred salt form having high water solubility for use herein is venlafaxine hydrochloride, other pharmaceutically salt forms such as venlafaxine fumarate, and venlafaxine succinate are contemplated. It is also contemplated within the scope of the invention that other pharmaceutical compounds having like characteristics can be formulated into extended release dosages by using the compositional techniques of the present invention. It is further contemplated within the scope of the invention that where desired, venlafaxine or a salt thereof may be used in combination with another anti-depressant agent or other pharmaceutical therapeutic class , which may be administered orally in the same dosage form in accordance with the present invention. It is also contemplated that venlafaxine or a salt
  • composition from about lOmg to about 600mg.
  • the present composition according to the invention is essentially comprised of one or more binders in an amount within the range of from about 0.1% to about 10% binder, preferably about 0.2% to about 5% binder and most preferably about 0.25% to about 4.5% binder by weight of the composition.
  • Binders usually are low viscosity polymers or non-polymeric materials and therefore they do not extend the release of a drug. Although binders improve appearance, hardness & friability of the preparation they are usually not intended to influence the disintegration or dissolution roles of active substance. Binders which are suitable for use herein include but are not limited to copovidone which is manufactured by free-radical polymerization of 6 parts of vinylpyrrolidone and 4 parts of vinyl acetate in isopropanol.
  • Copovidone is a white or yellowish-white spray-dried powder that has a relatively fine particle size and good flow properties. It has a typical slight odor and a faint taste in aqueous solutions. Because of the ratio of vinylpyrrolidone to vinyl acetate in copovidone, it is almost as universally soluble as polyvinyl pyrrolidone. It dissolves in extremely hydrophilic liquids such as water as well as in more hydrophobic solvents such as butanol. Copovidone has a molecular weight ranging from about 45000 to about 70000 and is available commercially in different grades and trade names such as Kollidon VA 64.
  • binders such as polyvinyl pyrrolidone (PVP) with a molecular weight ranging from about 4000 to about 1500000 and preferably about 30,000-1500000 can be used as a binder.
  • Polyvinylpyrrolidone is available in different grades based on K- value and molecular weights such as polyvinyl pyrrolidone with K value of 24-26, 29-32 or 85-95.
  • polyvinyl pyrrolidone with K value 85-95 Plasdone K-90/D®, Kollidon 90F®
  • binders can be used such as but not limited to an aqueous ethylcellulose dispersion such as Surelease®, clear E-7- 19040 (Colorcon, West Point,
  • PA hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxy ethyl cellulose,
  • polyvinyl alcohol sodium carboxy methyl cellulose
  • starches such as corn starch, modified corn starch, sugars, gum acacia and the like.
  • Venlafaxine hydrochloride granules prepared with copovidone have been found to have good compressibility.
  • Venlafaxine hydrochloride is essentially granulated with suitable binders, the binder concentration ranging from about 0.1% to about 10% binder, preferably about 0.2% to about 5% binder and most preferably about 0.25% to about 4.5% binder. Although concentrations above 4% can give also give binding effect, there is no substantial increase in binding hence higher concentrations are not employed or necessary.
  • the solvent used with the binder for granulation is preferably water. It is contemplated that other solvents such as isopropyl alcohol or the like can also be employed.
  • Venlafaxine hydrochloride granules so formed are uniformly dispersed in a controlled release matrix comprising of rate controlling polymers.
  • Controlled-release as used herein to describe a method and composition for making an active ingredient available to the biological system of a host.
  • a controlled release preparation according to the present invention is one that achieves slow release of a drug over an extended period of time, thereby extending the duration of drug action over that achieved by conventional delivery.
  • This admixture is typically compressed under pressure to produce a tablet. Drug is released from this tablet by diffusion and erosion.
  • the preferred polymeric matrices are those with a relatively high molecular weight.
  • release of the drug is achieved by allowing the gastric fluid to diffuse into the matrix where fluid dissolves the matrix-held drug and then diffuses outward while the matrix retains its integrity, or disintegrates at a rate that is considerably slower than the rate at which the drug is dissolved from matrix. Controlled release is thus achieved by the integrity of the matrix and the need for the gastric fluid to diffuse into the matrix to reach the drug.
  • Preferred polymers for the controlled release system of high solubility drug of the present invention are those which ensure rapid hydration of the polymer matrix to minimize variable and significant burst of drug, yet effectively control the release of drug being liberated from the discrete particles or drug granules.
  • the hydrophilic water-soluble polymers may be used individually or in combination.
  • polymers suitable for this invention include the polymers well known in the pharmaceutical art for their release retarding properties and may be selected from the group comprising acrylic polymers such as available as Eudragit RS, Eudragit RL, natural gums as xanthan gum, karaya gum, locust bean gum, guar gum, gelan gum, gum arabic, tragacanth, carrageenan, pectin, carboxymethyl cellulose (CMC) agar, alginic acid, sodium alginate polyvinylpyrrolidine, hydroxypropylcellulose, hydroxypropylmethyl cellulose, methyl cellulose, vinyl acetate copolymers, polyethylene oxide, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and derivatives and mixtures thereof.
  • acrylic polymers such as available as Eudragit RS, Eudragit RL, natural gums as xanthan gum, karaya gum, locust bean gum, guar gum, gelan gum, gum arabic,
  • Preferred polymers with appropriate hydration characteristics include hydroxypropylmethylcellulose 2208 USP (hydroxypropylmethylcellulose with a methoxyl content of 19-24% and a hydroxypropyl content of 7-12%), viscosity grades ranging from about 4000 to about 100,000cps and hydroxypropylmethylcellulose 2910 USP (hydroxypropylmethylcellulose with a methoxyl content of 28-30% and a hydroxypropyl content of 7-12%), viscosity grades ranging from about 3 to about 150 cps.
  • Another preferred polymer is sodium carboxy methylcellulose having viscosity of about 2000-50000 cps.
  • the amount of polymer relative to the drug may vary depending on the release rate desired, nature of the polymers and their physicochemical characteristics.
  • the amount of the polymer in the dosage form generally varies from about 10% to about 50% by weight of the composition.
  • the amount of polymers varies from about 15% to about 45% by weight of the dosage form.
  • the polymer concentration can be reduced as they are utilized optimally due to their incorporation in dry form. Additional excipients that are although not essential for the present invention, are required for the tableting process as known to those skilled in art, and may be suitably included.
  • composition of the invention therefore typically includes pharmaceutically acceptable excipients.
  • pharmaceutical excipients are routinely incorporated into solid dosage forms. This is done to ease the manufacturing process as well as to improve the performance of the dosage form.
  • Common excipients include diluents,
  • lubricants granulating aids, colorants, flavorants, surfactants, pH adjusters, anti-adherents and gildants etc.
  • excipients are routinely used in the dosage forms of this invention.
  • the present invention may additionally include one or more fillers or excipients in an amount within the range of from about 0 to about 90% by weight and preferably from about 1 to about 80% by weight such as lactose, sugar, corn starch, modified corn starch, mannitol, sorbitol, inorganic salts such as calcium carbonate and/or cellulose derivatives such as wood cellulose and microcrystalline cellulose.
  • fillers or excipients in an amount within the range of from about 0 to about 90% by weight and preferably from about 1 to about 80% by weight such as lactose, sugar, corn starch, modified corn starch, mannitol, sorbitol, inorganic salts such as calcium carbonate and/or cellulose derivatives such as wood cellulose and microcrystalline cellulose.
  • composition in the form of a tablet, it may include one or more tableting lubricants in an amount within the range of from about 0.2 to about 8% and preferably from about 0.5 to about 2% by weight of the composition, such as magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, polyethylene glycol, colloidal silicon dioxide, sodium stearyl fumarate, carnauba wax and the like and mixtures thereof.
  • Other conventional pharmaceutical ingredients which may optionally be present, include preservatives, stabilizers, and FD ScC colors etc.
  • composition made according to the present invention may be formulated as tablets within a capsule or a tablet. Most preferably, the composition is a tablet.
  • the tablet may optionally be coated with a thin layer of a film forming polymer or a pharmaceutical excipient.
  • the controlled release core formulation according to the invention is coated using a non-permeable film coating comprising a water insoluble polymer and an enteric coating polymer.
  • the non-permeable film coating is non-permeable to either acid or alkaline conditions for at least up to 4 hours.
  • the film coating influence the release properties of the tablet core.
  • the sustained release core releases the active pharmaceutical.
  • the active pharmaceutical is venlafaxine hydrochloride.
  • the delayed controlled release formulation according to the disclosure can be prepared in accordance with the following method of the invention.
  • a mixture essentially of venlafaxine hydrochloride and a suitable binder such as copovidone is granulated with a suitable solvent such as water to produce substantially uniform granules.
  • the granules are then dried and passed through a 1.5 to 2 mm aperture screen to break down agglomerates.
  • the resulting dry drug granules are blended with one or more hydrophilic polymers.
  • the resulting mix may then be coated within a non-permeable coating or optionally be mixed with diluents or fillers and finally may be lubricated with lubricant before pressing into tablets and then coated with a non- permeable coating.
  • venlafaxine hydrochloride is granulated with
  • providone K-30 dissolved in purified water and then further granulated with Surelease, clear E-I- 19040.
  • the resulting drug granules are blended with one or more hydrophilic polymers.
  • the resulting mix may then be coated within a non-permeable coating or optionally be mixed with diluents or fillers and finally may be lubricated with lubricant before pressing into tablets and then coated with a non-permeable coating.
  • the dosage form of present invention is a solid dosage form, preferably a tablet, which may vary in shape such as oval, triangle, almond, peanut, parallelogram, pentagonal, hexagonal,
  • trapezoidal The preferred shapes are oval and parallelogram forms.
  • a controlled release preparation according to the present invention is one that achieves slow release of a drug over an extended period of time, thereby extending the duration of drug action over that achieved by conventional delivery.
  • a preparation maintains a drug concentration in the blood within the therapeutic range for up to 12 hours or more.
  • Venlafaxine hydrochloride was sifted through a sieve no. #10.
  • the sifted material was granulated with providone K-30 dissolved in purified water and further coated using Surelease®, clear E-7- 19040 in a fluid bed processor.
  • the coated granules were sifted through a sieve No. #16,
  • the sifted granules were blended with the following excipients: Methocel K 100 M premium, Methocel K 4 M premium, Pharmatose DCL 15 and magnesium state.
  • the resulting blend was compressed into core tablets as follows:
  • a coating solution was prepared by adding ethylcellulose to acetone under stirring. Hypromellose phthalate was added and the solution was continued to be stirred. Purified water was added and the solution was continued to be stirred. Diethyl phthalate was added and the solution was continued to be stirred until a uniform coating solution was formed. The core tablets were coated with the uniform coating solution.
  • Table 1 The approximate amounts of the various ingredients are summarized in table 1 below. Table 1
  • Table 2 summarizes the approximate weight of ingredients of the individual tablets and the percentage of the weight of the coating in relation to the total tablet weight.
  • Table 3 summarizes the percent weight of ingredients of the individual tablets.
  • a therapeutic substance or a drug can be incorporated into the polymeric core.
  • the therapeutic substance can include any substance capable of exerting a therapeutic or prophylactic effect for the patient.
  • the therapeutic substance can be for inhibiting the activity of vascular smooth muscle cells.
  • the substance can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis.
  • the drug may include small molecule drugs, peptides, proteins, oligonucleotides, or double-stranded DNA.
  • therapeutic substances include aspirin, topiramate and quetiapine furmarate.
  • the substance can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances.
  • antineoplastics and/or antimitotics include paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride, and mitomycin.
  • antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin.
  • sodium heparin low molecular weight heparins
  • heparinoids examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Il
  • cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril, cilazapril or lisinopril, calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (.omega.-3- fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide.
  • angiopeptin angiotensin converting enzyme inhibitors such as captopril, cilazapril or lisinopri
  • an antiallergic agent is permirolast potassium.
  • Other therapeutic substances or agents which may be appropriate include alpha-interferon genetically engineered epithelial, endothelial, vascular smooth muscle cells, or other cells; cell cycle inhibitors such as rapamycin and its derivatives and analogs, and flavopiridol; the estrogen receptors such as estrogen, estrogen analogs, tamoxifen, and idoxifene; the retinoid receptors, such as retinal and retinoic acid; the PPAR alpha and gamma receptors such as troglitizone, rosiglitazone and pioglitazone; inhibitors of cell signaling including inhibitors of Ras and the MAP kinase cascade; inhibitors of receptor tyrosine kinases; steroid receptors such as clobetasol,
  • dexamethasone and derivatives or analogs thereof.
  • the delayed controlled release formulation having venlafaxine as an active ingredient it will be understood by those skilled in the art that the delayed controlled release formulation may be used for any active pharmaceutical, where it is desirable to delay the release of an extended release formulation.
  • the active pharmaceutical is chosen from one or more of the following categories/groups: abortifacient/interceptive, ace-inhibitor, .alpha.-adrenergic agonist, .beta.- adrenergic agonist, .alpha.-adrenergic blocker, .beta.
  • -adrenergic blocker adrenocortical steroid, adrenocortical suppressant, adrenocorticotropic hormone, alcohol deterrent, aldose reductase inhibitor, aldosterone antagonist, 5 -alpha reductase inhibitor, anabolic, analeptic, analgesic, androgen, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist, anorexic, antacid, anthelmintic, antiacne, antiallergic, antialopecia agent, antiamebic, antiandrogen, antianginal, antiarrhythmic, antiarteriosclerotic, antiarthritic/antirheumatic, antiasthmatic, antibacterial, antibacterial adjuncts, antibiotic, anticancer, anticholelithogenic, anticholesteremic, anticholinergic, anticoagulant, anticonvulsant, antidepressant, antidiabetic, antidiarrheal, antidiuretic,
  • depigmentor dermatitis herpetiformis suppressant, diagnostic aid, digestive aid, diuretic, dopamine receptor agonist, dopamine receptor antagonist, ectoparasiticide, emetic, enkephalinase inhibitor, enzyme, enzyme cofactor, enzyme inducer, estrogen, estrogen antagonist, expectorant, fibrinogen receptor antagonist, gastric and pancreatic secretion stimulant, gastric proton pump inhibitor, gastric secretion inhibitor, gastroprokinetic, glucocorticoid, .alpha.-glucosidase inhibitor, gonad-stimulating principle, gout suppressant, growth hormone inhibitor, growth hormone releasing factor, growth stimulant, hematinic, hematopoietic, hemolytic, hemostatic, heparin antagonist, hepatoprotectant, histamine H.sub.l - receptor antagonist, histamine H.sub.2 -receptor antagonist, HIV proteinase inhibitor, HMG CoA reductase inhibitor, hypnotic, hypo
  • alpha. -reductase inhibitor replenishers/supplements, respiratory stimulant, retroviral protease inhibitor, reverse transcriptase inhibitor, scabicide, sclerosing agent, sedative/hypnotic, serenic, serotonin noradrenaline reuptake inhibitor, serotonin receptor agonist, seratonin receptor antagonist, serotonin uptake inhibitor, skeletal muscle relaxant, somatostatin analog, spasmolytic, stool softener, succinylcholine synergist, sympathomimetic, thrombolytic, thromboxane A.sub.2 -receptor antagonist, thromboxane A.sub.2 -sythetase inhibitor, thyroid hormone, thyroid inhibitor, thyrotropic hormone, tocolytic, topical protectant, topoisomerase I inhibitor, topoisomerase II inhibitor, tranquilizer, ultraviolet screen, uricosuric, vasodilator, vasopressor, vasoprotectant
  • Wilson's disease treatment xanthine oxidase inhibitor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition à libération contrôlée retardée d'au moins une forme de venlafaxine. L'invention concerne précisément une composition à libération contrôlée retardée de chlorhydrate de venlafaxine obtenue grâce à un mélange de polymères dans la formulation de cœur. La formulation de cœur ayant des polymères de libération prolongée est enrobée d'un mélange de polymères non perméables formé d'un polymère insoluble dans l'eau et d'un polymère d'enrobage gastrorésistant, qui empêche la libération du médicament actif dans un acide ou dans une base pendant environ 4 heures. Lors de la désagrégation de l'enrobage non perméable, le médicament actif est libéré d'une manière prolongée à cause des polymères présents à l'intérieur de la formulation de cœur. La libération retardée empêche une libération importante de venlafaxine dans l'estomac.
EP07761266A 2006-06-07 2007-04-25 Compositions à libération retardée de formes à libération prolongée de venlafaxine Withdrawn EP2023906A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81154706P 2006-06-07 2006-06-07
PCT/US2007/067397 WO2007143290A2 (fr) 2006-06-07 2007-04-25 Compositions à libération retardée de formes à libération prolongée de venlafaxine

Publications (1)

Publication Number Publication Date
EP2023906A2 true EP2023906A2 (fr) 2009-02-18

Family

ID=38802169

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07761266A Withdrawn EP2023906A2 (fr) 2006-06-07 2007-04-25 Compositions à libération retardée de formes à libération prolongée de venlafaxine

Country Status (3)

Country Link
EP (1) EP2023906A2 (fr)
CA (1) CA2654361A1 (fr)
WO (1) WO2007143290A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200613B1 (fr) 2007-09-21 2018-09-05 The Johns Hopkins University Dérivés de phénazine et leurs utilisations
WO2010103365A2 (fr) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Composition à libération lente d'un agent thérapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007143290A3 *

Also Published As

Publication number Publication date
WO2007143290A3 (fr) 2008-10-16
CA2654361A1 (fr) 2007-12-13
WO2007143290A2 (fr) 2007-12-13

Similar Documents

Publication Publication Date Title
KR101234940B1 (ko) 안정한 서방출형의 경구 투여용 조성물
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
TWI241911B (en) Sustained release ranolazine formulations
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
AU2013344281B2 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EP2298416A2 (fr) Formulations de tramadol à libération prolongée avec une efficacite clinique de 24 heures
TWI302460B (en) Pharmaceutical compositions and use thereof
WO2002096392A1 (fr) Masquage du gout de medicaments hautement hydrosolubles
TW201630593A (zh) 特別用於治療注意力缺失症之方法及組成物
CA2451519C (fr) Comprime contenant de la cetirizine et de la pseudoephedrine
US20070042034A1 (en) High drug load formulations and dosage forms
US20090258067A1 (en) Modified release composition of at least one form of venlafaxine
US20090269402A1 (en) Modified release composition of at least one form of venlafaxine
EP1473030A1 (fr) Formulation de comprimé à libération prolongée du venlafaxine
US20120201887A1 (en) Pharmaceutical Formulation
WO2007143290A2 (fr) Compositions à libération retardée de formes à libération prolongée de venlafaxine
WO2026062542A1 (fr) Formulations à libération modifiée de méthylphénidate
KR101199654B1 (ko) 안정한 서방출형의 경구 투여용 조성물
EP2074993A1 (fr) Comprimés enrobés contenant venlaflaxine à libération modifiée
AU2002305737A1 (en) Taste-masking of highly water-soluble drugs
HK1210042B (en) Pharmaceutical compositions comprising hydromorphone and naloxone

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081210

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101102